Provided by Tiger Fintech (Singapore) Pte. Ltd.

AzurRx Biopharma Inc.

3.45
+0.0000
Volume:- -
Turnover:2.20M
Market Cap:34.33M
PE:-0.22
High:3.45
Open:3.45
Low:3.45
Close:3.45
Loading ...
Jun 01, 2020

Major Issues Report

8-K - Current report
May 15, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 01, 2020

Major Issues Report

Current report, item 5.02
Apr 29, 2020

[Rev.]Annual Report

[Amend] Annual report [Section 13 and 15(d), not S-K Item 405]
Apr 21, 2020

Major Issues Report

Current report, items 8.01 and 9.01
Apr 14, 2020

Major Issues Report

8-K - Current report
Mar 30, 2020

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 27, 2020

Major Issues Report

8-K - Current report
Mar 16, 2020

Major Issues Report

Current report, item 7.01
Mar 02, 2020

Major Issues Report

8-K - Current report
Feb 14, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Jan 29, 2020

Beneficial Ownership Change

[Amend] General statement of acquisition of beneficial ownership
Jan 22, 2020

Major Issues Report

Current report, item 8.01
Jan 14, 2020

Major Issues Report

Current report, items 1.01, 2.03, 3.02, and 9.01
Jan 13, 2020

Correspondence

[Cover]Correspondence
Jan 13, 2020

[Amend]Public Prospectus

[Amend] General form for registration of securities under the Securities Act of 1933
Jan 13, 2020

Major Issues Report

Current report, items 8.01 and 9.01
Jan 06, 2020

Major Issues Report

Current report, items 1.01, 2.03, 3.02, 5.02, and 9.01
Dec 31, 2019

Public Prospectus

General form for registration of securities under the Securities Act of 1933
Dec 30, 2019

Major Issues Report

Current report, items 1.01, 2.03, 3.02, 5.03, 8.01, and 9.01